Lupus intestinal pseudo-obstruction and hydronephrosis

Case report

Brittany L. Adler, MD*, Homa Timlin, MD, Julius Birnbaum, MD

Abstract

Introduction: Intestinal pseudo-obstruction (IPO) is a rare and life-threatening complication of lupus.

Patient Concerns: A patient with long-standing lupus developed recurrent abdominal pain and distension as well as nausea and emesis.

Diagnosis: Imaging showed dilated small bowel loops with air-fluid levels and bowel wall thickening. She also had bilateral hydronephrosis.

Interventions: She was given high-doses of intravenous steroids and cyclophosphamide.

Outcomes: Her symptoms resolved within a week of starting immunosuppression. She was eventually transitioned to mycophenolate mofetil. She remained in remission and immunosuppression was successfully stopped after 1 year.

Conclusions: Intestinal pseudo-obstruction is a rare complication of lupus that is often seen in association with ureterohydronephrosis and interstitial cystitis. This clinical syndrome is thought to be because of smooth muscle dysmotility of the gastrointestinal and genitourinary tracts, although the exact mechanism of dysmotility remains unknown. This condition is often responsive to immunosuppression if recognized and treated promptly.

Abbreviations: CT = computed tomography, GI = gastrointestinal, GU = genitourinary, IPO = intestinal pseudo-obstruction, LMV = lupus mesenteric vasculitis, MRI = magnetic resonance imaging, SLE = systemic lupus erythematosus.

Keywords: dysmotility, hydronephrosis, lupus, pseudo-obstruction

1. Introduction

Intestinal pseudo-obstruction (IPO) is a rare complication of systemic lupus erythematosus (SLE) that is characterized by ineffective propulsion of the intestine resulting in obstructive symptoms without a mechanical cause. SLE-IPO is a relatively rare entity that is likely underdiagnosed. In one recent series of hospitalized patients with SLE, the prevalence of lupus intestinal pseudo-obstruction (SLE-IPO) was approximately 2% and SLE-IPO encompasses about 5% of all cases of SLE-induced abdominal pain requiring admission to the hospital. SLE-IPO clinically manifests as abdominal pain and distension, nausea and emesis.

There is a striking association between intestinal pseudo-obstruction in SLE and genitourinary (GU) complications including hydronephrosis, hydrourereter, and cystitis. Approximately, 60% of SLE patients with IPO also have coinciding ureterohydronephrosis and among these patients many have reduced bladder capacity and histologic evidence of interstitial cystitis. SLE-interstitial cystitis can often be distinguished histologically from idiopathic interstitial cystitis by the presence of immunofluorescent deposits in blood vessel walls of the urinary bladder. Gall bladder wall thickening, biliary and pancreatic duct dilation, and esophageal dysmotility are also associated findings with SLE-IPO. Concurrent involvement of the gastrointestinal (GI) and GU tracts in SLE should strongly raise suspicion for intestinal pseudo-obstruction.

IPO can occur at any time during the disease course of SLE, and in two-thirds of cases it can be a presenting symptom of SLE. SLE-IPO is especially challenging to diagnose when IPO develops before an underlying diagnosis of SLE is established. IPO typically occurs in active SLE, although there are reports of IPO in patients with quiescent disease. Compared to patients without IPO, SLE patients with IPO tend to have more alopecia, polyserositis, leukocytopenia, elevated C-reactive protein (CRP), hypoaluminaemia, hypocomplementemia, and positive SS-A/Ro autoantibodies. Approximately two-thirds of patients with SLE-IPO have SS-A/Ro autoantibodies. Pyeloureterectomy,
peritonitis, hypocomplementemia, hypoalbuminemia, and elevated CRP have been identified as risk factors for IPO in patients with SLE. Owing to the variability in SLE features among patients with IPO, IPO should be considered in all SLE patients presenting with GI symptoms.

SLE-IPO is thought to result from smooth muscle dysmotility of the GI tract, and associated hydronephrosis and hepatobiliary dilatation likely also result from smooth muscle dysmotility. Although the exact pathophysiology remains unknown, proposed mechanisms for smooth muscle damage include myopathic, neurogenic, and vasculitic processes. Pathogenic autoantibodies targeting smooth muscle and immune complex deposition on the muscle and/or nerve are possible immunologic mechanisms that have been implicated. To date no specific autoantibodies have been identified among patients with SLE-IPO.

There are several published reports of GI histopathology from patients with SLE-IPO, all of which were obtained from post-mortem examinations or from intestinal resections. These reports showed damage to the muscularis layer of the GI tract with sparing of the muscularis mucosa. In particular, the outer longitudinal layer of the muscularis propria was disproportionately affected with fibrosis and loss of smooth muscle, with relative sparing of the inner layer of the muscularis propria. Hill et al. captured the progression of the disease on sequential biopsies, and showed that in the early phases there is extensive myocyte necrosis and inflammation within the muscularis propria, which later develops into atrophy and fibrosis with decreased number of smooth muscle cells. Inversion of the GI tract was intact and there was no evidence of ganglionitis or vasculitis. Taken together, these studies are suggestive of a primary myopathic process.

Herein we report on a case of lupus intestinal pseudo-obstruction and associated ureterohydronephrosis. This case demonstrates the difficulty in clinically distinguishing lupus-IPO from lupus mesenteric vasculitis (LMV), 2 disease entities that are commonly mistaken in the literature. It also highlights the importance of recognizing this syndrome as it is usually responsive to immunosuppression and can lead to significant morbidity without prompt treatment.

2. Case report

A 40-year-old African-American female with long-standing SLE presented to the emergency room with recurrent abdominal pain, distension, and emesis. She had a 10-year history of SLE and immunological findings consistent with the 2012 SLICC criteria for SLE. Clinical features included oral ulcers, alopecia, and malar rash that were successfully treated with hydroxychloroquine 400 mg per-oral per day (QD). Immunological findings included anti-nuclear antibodies at a titer of 1:640 (speckled pattern), positive SS-A/Ro antibodies, positive ribonucleoprotein antibodies, and hypocomplementemia.

Her first episode of GI symptoms occurred 8 months before our initial evaluation when she was 8 weeks pregnant. At that time, magnetic resonance imaging (MRI) of her abdomen showed a small bowel obstruction, ascites, and new right-sided hydronephrosis. She had a diagnostic laparoscopy that did not reveal a mechanical obstruction or adhesions. Therefore, it was thought that these findings may be reflective of SLE disease activity. She was treated empirically with 60 mg of prednisone and her small bowel obstruction resolved within a week of starting prednisone. Around this time she experienced a spontaneous abortion.

Antiphospholipid antibodies were negative. The prednisone was tapered off over the course of several months, and she returned to her usual state of health. Five months before our evaluation she developed recurrent abdominal pain, distension, and emesis. A computed tomography (CT) scan of her abdomen showed small bowel distension and thickened bowel loops with air–fluid levels, as well as ascites and marked bilateral hydronephrosis. Mucosal biopsies of her stomach, small bowel, and colon from esophagogastroduodenoscopy and colonoscopy were normal. She was again treated empirically with 60 mg of prednisone and had rapid resolution of her symptoms within weeks.

Several weeks before our evaluation, she returned to medical attention with recurrent abdominal pain and distension as well as new flank pain and dysuria. Urine culture grew *Escherichia coli* and she was diagnosed with pyelonephritis and treated with antibiotics. She was also empirically given 40 mg of prednisone for her GI symptoms. The pyelonephritis resolved, but her abdominal pain and distension progressed even on 40 mg of prednisone and she presented to the hospital. On presentation, her abdomen was markedly distended and tympanic to percussion with hypoactive bowel sounds and mild guarding. CT of her abdomen was similar to previous imaging and showed ascites, significant dilation and thickening of bowel wall loops with associated mucosal enhancement (Fig. 1) and bilateral hydronephrosis (Fig. 2). Her laboratory evaluation was notable for a mild leukocytosis (white blood cell count 11.4 K/μm without bands), hemoglobin 11.7 g/dL, platelets 441 K/μm, creatinine 0.76 mg/dL, normal liver function tests, normal lactate, albumin 3.1 g/dL, c-reactive protein 6.9 mg/dL, and sedimentation rate of 6 mm/h. Stool cultures and infectious work-up were negative. SLE laboratories were notable for a negative anti-dsDNA antibody, low complements (C3 44 mg/dL, C4 6 mg/dL), urine analysis without red blood cells, and 24-hour urine with 341 mg of protein. Renal biopsy showed membranous lupus glomerulopathy (class V) with focal mild mesangial proliferation. The Mayo paraneoplastic panel was negative for autoantibodies associated with GI dysmotility, including voltage-gated calcium channel antibodies (P/Q-type and N-type), voltage-gated potassium channel antibodies, acetylcholine receptor antibodies.

**Figure 1.** Large dilated bowel loops and bowel wall thickening in lupus intestinal pseudo-obstruction.
Intestinal mucosal biopsies are often normal or unrevealing and can be avoided if there is a high suspicion for rule out a mechanical obstruction, although this is typically normal histopathology. Patients often undergo laparotomy to the patient had a normal laparotomy and 2 colonoscopies with symptoms for the past 2 years.

Patients may not need prolonged treatment to prevent relapses of this disease.

3. Discussion

In this report we present a case of a patient with long-standing SLE presenting with recurrent intestinal pseudo-obstruction and associated hydroureteronephrosis. She had a rapid and sustained response to treatment with immunosuppression. This case highlights several important lessons regarding diagnosis and management of this syndrome.

The diagnosis of lupus-IPO is typically made based on clinical presentation and imaging. CT shows dilated bowel loops with air–fluid levels, bowel wall thickening, and ascites. In this case the patient had a normal laparotomy and 2 colonoscopies with normal histopathology. Patients often undergo laparotomy to rule out a mechanical obstruction, although this is typically unrevealing and can be avoided if there is a high suspicion for SLE-IPO. Intestinal mucosal biopsies are often normal or show nonspecific edema because the pathology is deeper in the smooth muscle layer, which underscores the importance of having a high level of suspicion to make a clinical diagnosis. If the diagnosis is still unclear, manometry often demonstrates abnormalities throughout the GI tract, including esophageal aperistalsis, delayed gastric emptying, decreased lower esophageal sphincter pressure, and hypomotility of the stomach and small intestine.

This case also highlights the challenge of distinguishing lupus-IPO from LMV without a full-thickness biopsy. These 2 diseases are often confused clinically and in the literature. LMV is an ischemic enteritis secondary to vasculitis or vascular thrombosis, whereas SLE-IPO results from dysmotility of intestinal smooth muscle. Both diseases can cause bowel wall edema and thickening, ascites, and bowel dilatation on imaging. Three classic radiologic signs are sometimes seen in LMV and can help narrow the differential, including mesenteric abnormalities such as engorgement of mesenteric vessels or increased number of vessels (“Combi sign”), bowel wall thickening and enhancement that looks like a target (the “target sign”), and increased attenuation of mesenteric fat. Although these imaging findings may suggest a diagnosis of LMV, we note that ischemia and bowel wall enhancement can also be seen in SLE-IPO. In the present case, the diagnosis of SLE-IPO was made based on the presence of concurrent urinary tract abnormalities such as ureterohydronephrosis and/or cystitis, which are typically absent in lupus-LMV.

Patients with SLE-IPO and urinary involvement often respond rapidly to immunosuppression, although the necessity of starting a disease-modifying antirheumatic drug and the duration of treatment required remains unknown based on previous reports. SLE-IPO can cause significant morbidity and mortality if not promptly recognized and treated. One study reported an in-hospital mortality rate of 7% among patients with SLE-IPO, which was often from sepsis or bowel perforation. If IPO is not treated, the smooth muscle layer can become atrophic and fibrotic and will no longer be reversible with immunosuppression. In severe cases of chronic intestinal pseudo-obstruction, patients may become dependent on total parenteral nutrition.

There are reports of successful treatment with cyclophosphamide, mycophenolate mofetil, azathioprine, cyclosporin A, and intravenous immunoglobulin, although it is unclear whether these patients may have improved with steroids alone. In the present case, treatment with prednisone alone was not sufficient and the patient required initiation of a disease-modifying antirheumatic drug. This patient was able to successfully stop all immunosuppression after 1 year and remain in remission without any GI symptoms, which suggests that patients may not need prolonged treatment to prevent relapses of this disease.

4. Conclusion

Intestinal pseudo-obstruction is a rare complication of SLE that should be considered in any SLE patient presenting with GI symptoms. Early recognition is important to avoid unnecessary surgical intervention and permanent damage to the GI tract. It is often difficult to differentiate SLE-IPO from LMV without a full-thickness biopsy, although the presence of ureterohydronephrosis and interstitial cystitis should strongly raise suspicion for IPO. It is thought to result from smooth muscle dysmotility, although the precise immunologic mechanism remains unknown. Prompt treatment of IPO is most efficacious in the earliest stages, and can induce remission of IPO as well as extraenteric complications.

Author contributions

Conceptualization: Brittany Adler, Julius Birnbaum.
Writing – original draft: Brittany Adler.
Writing – review & editing: Homa Timlin, Julius Birnbaum.
References

[1] Nguyen H, Khanna N. Intestinal pseudo-obstruction as a presenting manifestation of systemic lupus erythematosus: case report and review of the literature. South Med J 2004;97:186–9.
[2] Zhang L, Xu D, Yang H, et al. Clinical features, morbidity, and risk factors of intestinal pseudo-obstruction in systemic lupus erythematosus: a retrospective case-control study. J Rheumatol 2016;43:559–64.
[3] Yuan S, Liu F, Chen D, et al. Clinical features and associated factors of abdominal pain in systemic lupus erythematosus. J Rheumatol 2013;40:2015–22.
[4] Wang JL, Liu G, Liu T, et al. Intestinal pseudo-obstruction in systemic lupus erythematosus: a case report and review of the literature. Medicine (Baltimore) 2014;93:e248.
[5] Alexopoulos A, Andrianakos A, Dourakis SP. Intestinal pseudo-obstruction and ureterohydronephrosis in a patient with systemic lupus erythematosus and overlapping syndrom. Clin Exp Rheumatol 1989;7:533–6.
[6] Moriuchi J, Ichikawa Y, Takaya M, et al. Lupus cystitis and perforation of the small bowel in a patient with systemic lupus erythematosus. Medicine (Baltimore) 2014;93:e248.
[7] Mok M, Wong R, Lau C. Intestinal pseudo-obstruction in systemic lupus erythematosus patients with intestinal pseudo-obstruction and/or ureterohydronephrosis. Medicine (Baltimore) 2015;94:e419.
[8] Xu N, Zhao J, Liu J, et al. Clinical analysis of 61 systemic lupus erythematosus patients with intestinal pseudo-obstruction and/or urerohydronephrosis. Medicine (Baltimore) 2014;93:e248.
[9] Alarcón-Segovia D, Abud-Mendoza C, Reyes-Gutiérrez E, et al. Involvement of the urinary bladder in systemic lupus erythematosus. A pathologic study. J Rheumatol 1984;11:208–10.
[10] Kim HJ, Park JY, Kim SM, et al. Systemic lupus erythematosus with obstructive uropathy: case report and review. J Korean Med Sci 1995;10:462–9.
[11] Narváez J, Pérez-Vega C, Castro-Bohorquez FJ, et al. Intestinal pseudo-obstruction in systemic lupus erythematosus. Scand J Rheumatol 2003;32:191–5.
[12] Weisman MH, McDaid EC, Wilson CB. Studies of the pathogenesis of interstitial cystitis, obstructive uropathy, and intestinal malabsorption in a patient with systemic lupus erythematosus. Am J Med 1981;70:873–81.
[13] Pardos-Gea J, Ordi-Ros J, Selva A, et al. Chronic intestinal pseudo-obstruction associated with biliary tract dilation in a patient with systemic lupus erythematosus. Lupus 2005;14:328–30.
[14] Kansal A, Jain A, Thenozi S, et al. Intestinal pseudo-obstruction associated with biliary tract dilation in a patient with systemic lupus erythematosus. Lupus 2013;22:87–91.
[15] Perlemuter G, Chaussade S, Wechsler B, et al. Chronic intestinal pseudo-obstruction in systemic lupus erythematosus. Gut 1998;43:117–22.
[16] Xu D, Lin J. Urinary tract involvement in systemic lupus erythematosus: coexistence with lupus mesentric vasculitis or intestinal pseudo-obstruction? Semin Arthritis Rheum 2015;44:e9.
[17] Leonardí G, de Botroli N, Bellini M, et al. Intestinal pseudo-obstruction in inactive systemic lupus erythematosus: An unusual finding. World J Gastrointest Pharmacol Ther 2010;1:133–6.
[18] Huang Q, Lai W, Yuan C, et al. Predictors of intestinal pseudo-obstruction in systemic lupus erythematosus complicated by digestive manifestations: data from a Southern China lupus cohort. Lupus 2016;25:248–54.
[19] Cacoub P, Benhamou Y, Barbet P, et al. Systemic lupus erythematosus and chronic intestinal pseudoobstruction. J Rheumatol 1993;20:377–81.
[20] Hill PA, Dwyer KM, Power DA. Chronic intestinal pseudo-obstruction in systemic lupus erythematosus due to intestinal smooth muscle myopathy. Lupus 2000;9:458–63.
[21] Yang C, Chen S, Gauth JP, et al. Smooth-muscle myopathy in systemic lupus erythematosus presenting with intestinal pseudo-obstruction. Am J Gastroenterol 2016;111:1501–2.
[22] Kim N, Kim J. JNM Journal of Neurogastroenterology and Motility Intestinal Pseudo-obstruction: initial manifestation of systemic lupus erythematosus. J Neurogastroenterol Motil 2011;17:2093–879.
[23] Dhamija R, Tan KM, Pittock SJ, et al. Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. Clin Gastroenterol Hepatol 2008;6:988–92.
[24] Chen Y-Y, Yen H-H, Hsu Y-T. Intestinal pseudo-obstruction as the initial presentation of systemic lupus erythematosus: the need for enteroscopic evaluation. Gastrointest Endosc 2003;62:984–7.
[25] Jin P, Ji X, Zhi H, et al. A review of 42 cases of intestinal pseudo-obstruction in patients with systemic lupus erythematosus based on case reports. Hum Immunol 2015;76:695–700.
[26] Antonucci A, Fronzoni L, Ciglioni L, et al. Chronic intestinal pseudo-obstruction, World J Gastroenterol 2008;14:2953–61.
[27] Yuan S, Ye Y, Chen D, et al. Lupus mesenteric vasculitis: clinical features and associated factors for the recurrence and prognosis of disease. Semin Arthritis Rheum 2014;43:759–66.
[28] Janssens P, Arnaud L, Galicier L, et al. Lupus enteritis: from clinical findings to therapeutic management. Orphanet J Rare Dis 2013;8:67.
[29] Huang YT, Chung TW, Wang JJ. Target sign in lupus enteritis. QJM 2017;110:401–6.
[30] Park F-D, Lee J-K, Madduri G-D, et al. Generalized megaviscera of lupus: enteroscopic evaluation. Gastrointest Endosc 2005;62:984–7.
[31] Luman W, Chua KB, Cheong WK, MW, et al. Gastrointestinal manifestations of systemic lupus erythematosus. Singapore Med J 2001;42:428.
[32] Oh DJ, Yang JN, Lim YJ, et al. Intestinal pseudo-obstruction as an initial manifestation of systemic lupus erythematosus. Intest Res 2015;13: 282–6.
[33] Alberto García López C, Laredo-Sánchez F, Malagón-Rangel J, et al. Intestinal pseudo-obstruction in patients with systemic lupus erythematosus: a real diagnostic challenge 2014;20:11443–50.